IS8439A - Nýjar kínólín afleiður - Google Patents

Nýjar kínólín afleiður

Info

Publication number
IS8439A
IS8439A IS8439A IS8439A IS8439A IS 8439 A IS8439 A IS 8439A IS 8439 A IS8439 A IS 8439A IS 8439 A IS8439 A IS 8439A IS 8439 A IS8439 A IS 8439A
Authority
IS
Iceland
Prior art keywords
quinoline derivatives
new quinoline
new
derivatives
quinoline
Prior art date
Application number
IS8439A
Other languages
English (en)
Inventor
Hong Yufeng
Steven Kania Robert
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34738830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8439(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS8439A publication Critical patent/IS8439A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS8439A 2003-12-23 2006-05-04 Nýjar kínólín afleiður IS8439A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53272503P 2003-12-23 2003-12-23
PCT/IB2004/004151 WO2005063739A1 (en) 2003-12-23 2004-12-13 Novel quinoline derivatives

Publications (1)

Publication Number Publication Date
IS8439A true IS8439A (is) 2006-05-04

Family

ID=34738830

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8439A IS8439A (is) 2003-12-23 2006-05-04 Nýjar kínólín afleiður

Country Status (33)

Country Link
US (2) US7381824B2 (is)
EP (1) EP1699780A1 (is)
JP (1) JP4503022B2 (is)
KR (1) KR100807920B1 (is)
CN (1) CN1890234A (is)
AP (1) AP2006003619A0 (is)
AR (1) AR048292A1 (is)
AU (1) AU2004309166B2 (is)
BR (1) BRPI0418102A (is)
CA (1) CA2551508C (is)
CR (1) CR8482A (is)
EA (1) EA009994B1 (is)
EC (1) ECSP066671A (is)
GE (1) GEP20084572B (is)
GT (1) GT200400274A (is)
HN (1) HN2004000544A (is)
IL (1) IL175947A (is)
IS (1) IS8439A (is)
MA (1) MA28396B1 (is)
MX (1) MXPA06007242A (is)
MY (1) MY139446A (is)
NL (1) NL1027847C2 (is)
NO (1) NO20063382L (is)
NZ (1) NZ547009A (is)
OA (1) OA13349A (is)
PE (1) PE20050757A1 (is)
SG (1) SG141459A1 (is)
TN (1) TNSN06200A1 (is)
TW (1) TWI331148B (is)
UA (1) UA82577C2 (is)
UY (1) UY28692A1 (is)
WO (1) WO2005063739A1 (is)
ZA (1) ZA200603657B (is)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084572B (en) * 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
EP1711495A2 (en) * 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
EP1915368A1 (en) * 2005-08-08 2008-04-30 Pfizer, Inc. Salts and polymorphs of a vergf-r inhibitor
CA2632384A1 (en) * 2005-12-05 2007-06-14 Pfizer Products Inc. Methods of preparing a vegf-r inhibitor
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
US8163923B2 (en) * 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
ES2465673T3 (es) 2007-04-16 2014-06-06 Hutchison Medipharma Enterprises Limited Derivados de pirimidina
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
MX2011004018A (es) 2008-10-14 2011-06-24 Ning Xi Compuestos y metodos de uso.
IT1393351B1 (it) * 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
CA2752421C (en) * 2009-03-21 2013-08-06 Ning Xi Amino ester derivatives, salts thereof and methods of use
CN110483499A (zh) 2009-11-05 2019-11-22 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CA2829131C (en) 2011-03-04 2018-11-20 Glaxosmithkline Intellectual Property (No.2) Limited Amino-quinolines as kinase inhibitors
FR2973703A1 (fr) * 2011-04-08 2012-10-12 Univ Provence Aix Marseille 1 Derives de 4-arylcoumarine et de 4-arylquinoleine, leurs utilisations therapeutiques et leur procede de synthese
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基-喹啉類
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
AU2014220300B2 (en) 2013-02-21 2016-10-13 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN103524409B (zh) * 2013-09-26 2015-09-02 上海仁力医药科技有限公司 喹啉类化合物及其制备方法与应用
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
CN105213394B (zh) * 2014-06-06 2019-04-09 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
CN104628686A (zh) * 2015-01-27 2015-05-20 南通恒盛精细化工有限公司 一种带酰胺侧链的苯并呋喃制备工艺
WO2016161952A1 (zh) * 2015-04-07 2016-10-13 广东众生药业股份有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
BR112018005208B1 (pt) 2015-09-17 2023-12-12 Marvin J. Miller Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼd及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
JP6917448B2 (ja) * 2016-09-30 2021-08-11 広東衆生睿創生物科技有限公司Guangdong Raynovent Biotech Co.,Ltd. チロシンキナーゼ阻害剤の結晶形、塩形態及び製造方法
CN107337634B (zh) * 2017-08-28 2019-07-09 新发药业有限公司 一种阿贝西利中间体化合物的制备方法
FR3080620B1 (fr) * 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
WO2020210481A1 (en) * 2019-04-12 2020-10-15 Nation Health Research Institutes Heterocyclic compounds as kinase inhibitors for therapeutic uses
CN116478130B (zh) * 2022-01-21 2025-05-30 深圳默元生物科技有限公司 N-羟基喹啉甲酰胺化合物及其用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE317376B (is) 1961-07-10 1969-11-17 Roussel Uclaf
FR2077455A1 (en) 1969-09-03 1971-10-29 Aries Robert 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3936461A (en) 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2498187A1 (fr) 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
JPS62168137A (ja) 1985-12-20 1987-07-24 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料およびその処理方法
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2108889A1 (en) 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
CA2114727C (en) 1991-08-02 1996-12-10 Mikel P. Moyer Quinoline derivatives as immunostimulants
GB9127252D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
RU2137762C1 (ru) 1994-02-23 1999-09-20 Пфайзер Инк. 4-гетероциклил-замещенные производные хиназолина, фармацевтическая композиция
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (is) 1994-11-12 1997-12-01 Zeneca Ltd
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP0831829B1 (en) 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
AU2912997A (en) 1996-06-24 1998-01-14 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
JPH11512750A (ja) 1996-06-27 1999-11-02 ファイザー インク. 2―(2―オキソ―エチリデン)―イミダゾリジン―4―オンの誘導体およびファルネシル蛋白質トランスフェラーゼ阻害物質としてのそれらの使用法
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PL331154A1 (en) 1996-07-13 1999-06-21 Glaxo Group Ltd Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase
ATE300521T1 (de) * 1996-09-25 2005-08-15 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
KR20000057228A (ko) 1996-11-27 2000-09-15 디. 제이. 우드, 스피겔 알렌 제이 축합된 비사이클릭 피리미딘 유도체
EP0968206B8 (en) 1997-02-19 2007-01-24 Berlex, Inc. N-heterocyclic derivatives as nos inhibitors
JP2002511852A (ja) 1997-05-07 2002-04-16 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての2−インドリノン誘導体
EP0980258A1 (en) 1997-05-12 2000-02-23 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
WO1998054093A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999010349A1 (en) 1997-08-22 1999-03-04 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999024440A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
AU3850299A (en) 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
US6395734B1 (en) 1998-05-29 2002-05-28 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
CZ303899B6 (cs) * 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
EP1140183A1 (en) 1998-12-23 2001-10-10 G.D. Searle & Co. Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
DE60033857T2 (de) 1999-01-22 2007-10-25 Kirin Beer K.K. Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität
CZ305827B6 (cs) 1999-02-10 2016-03-30 Astrazeneca Ab Indolové deriváty
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US7135466B2 (en) 1999-12-24 2006-11-14 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
DE60018216T2 (de) 1999-12-24 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Kondensierte purinderivate
JP2003527441A (ja) 2000-03-22 2003-09-16 グラクソ グループ リミテッド 細胞周期を阻止する薬剤及び抗体を含む医薬
EP1436000A2 (en) 2000-03-31 2004-07-14 Imclone Systems, Inc. Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
CA2407858C (en) 2000-05-12 2015-10-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
AU2001276536B2 (en) * 2000-08-09 2007-01-04 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
KR100389127B1 (ko) 2000-10-09 2003-06-25 동부한농화학 주식회사 벤조피라닐 헤테로고리 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
AU2001296821A1 (en) 2000-10-12 2002-04-22 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
RU2264389C3 (ru) 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
EP1810715A3 (en) 2000-11-22 2009-12-16 Novartis AG Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
WO2002064170A1 (en) 2001-02-09 2002-08-22 Children's Medical Center Corporation A method for treating cancer and increasing hematocrit levels
CA2453474A1 (en) 2001-07-13 2003-01-23 Imclone Systems Incorporated Vegfr-1 antibodies to treat breast cancer
WO2003033472A1 (fr) 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
NZ532418A (en) 2001-10-25 2007-02-23 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor and a microtubule interfering agent
EP1483268A2 (en) * 2002-03-01 2004-12-08 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
KR100942073B1 (ko) 2002-08-23 2010-02-12 기린 홀딩스 가부시키가이샤 TGF β 저해 활성을 갖는 화합물 및 그것을 포함하여 이루어지는 의약 조성물
MXPA05001536A (es) 2002-08-30 2005-04-19 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
GEP20084572B (en) * 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives

Also Published As

Publication number Publication date
US7923457B2 (en) 2011-04-12
UY28692A1 (es) 2005-07-29
EA009994B1 (ru) 2008-06-30
MA28396B1 (fr) 2007-01-02
AP2006003619A0 (en) 2006-06-30
KR100807920B1 (ko) 2008-02-27
PE20050757A1 (es) 2005-10-31
MY139446A (en) 2009-10-30
AU2004309166A1 (en) 2005-07-14
US20090069316A1 (en) 2009-03-12
NZ547009A (en) 2009-09-25
JP4503022B2 (ja) 2010-07-14
CA2551508A1 (en) 2005-07-14
US7381824B2 (en) 2008-06-03
NL1027847C2 (nl) 2006-04-19
MXPA06007242A (es) 2006-08-18
IL175947A (en) 2012-08-30
JP2007516273A (ja) 2007-06-21
CN1890234A (zh) 2007-01-03
KR20060101548A (ko) 2006-09-25
GT200400274A (es) 2005-09-20
HN2004000544A (es) 2010-06-09
WO2005063739A1 (en) 2005-07-14
AU2004309166B2 (en) 2008-02-21
EA200600892A1 (ru) 2006-12-29
NL1027847A1 (nl) 2005-06-27
UA82577C2 (en) 2008-04-25
SG141459A1 (en) 2008-04-28
ECSP066671A (es) 2006-10-25
AR048292A1 (es) 2006-04-19
IL175947A0 (en) 2006-10-05
TWI331148B (en) 2010-10-01
ZA200603657B (en) 2007-08-29
NO20063382L (no) 2006-09-20
GEP20084572B (en) 2008-12-25
OA13349A (en) 2007-04-13
CA2551508C (en) 2011-08-09
TW200526218A (en) 2005-08-16
US20050137395A1 (en) 2005-06-23
TNSN06200A1 (fr) 2007-11-15
BRPI0418102A (pt) 2007-04-27
CR8482A (es) 2007-12-17
EP1699780A1 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
IS8439A (is) Nýjar kínólín afleiður
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
LU92427I2 (fr) Aripiprazole
ATE352550T1 (de) Chinazolinderivate
ATE420066T1 (de) Amidoacetonitrilderivate
DK1611131T3 (da) Pyrazolopyridin-derivater
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
ATE450506T1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
DK2248807T3 (da) N-Phenyl-2-pyrimidinaminderivater
IS8364A (is) N-þíasól-2-ýl-bensamíð afleiður
DE602004022180D1 (de) Chinazolinderivate
DK1606277T3 (da) Imidazol-4-yl-ethynyl-pyridinderivater
IS8180A (is) Nýjar besímídasólafleiður
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
ATE423771T1 (de) Tetrahydrochinolinderivate
DK1706373T3 (da) Amidoacetonitrilderivater
DE60311233D1 (de) Chinolinderivate
IS8045A (is) Púrín-6-ón-afleiður
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
IS2647B (is) Tetrahýdrókínólín afleiður